AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $263.88. The company's market cap stands at 466.31B, with a P/E ratio of 75.29 and a dividend yield of 2.56%.
During the trading session on 2026-09-29, AbbVie(ABBV) shares reached a daily high of $268.93 and a low of $261.52. At a current price of $263.88, the stock is +0.9% higher than the low and still -1.9% under the high.
Trading activity shows a volume of 1.91M, compared to an average daily volume of 4M.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
ABBV News
...
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Grou...
AbbVie (ABBV) is investing in its AI infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at w...
Analyst ratings
75%
of 32 ratingsMore ABBV News
BofA analyst Tim Anderson raised the firm’s price target on AbbVie (ABBV) to $289 from $282 and keeps a Buy rating on the shares. The company is well positioned...
AbbVie reported that the FDA approved JUVMO, or tavapadon, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, supported...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s (NYSE:ABBV) Juvmo (tavapadon) tablets as the first and only selective D1/D5 recept...
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (ABBV) Juvmo (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for tr...
Key Points AbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs. Johnson & Jo...
AbbVie (ABBV) just picked up a fresh regulatory win in oncology, with Health Canada granting a new follicular lymphoma indication for EPKINLY in combination the...
Choosing between AbbVie (ABBV +0.01%) and Eli Lilly and Co (LLY +2.69%) requires weighing established income against explosive growth. Both companies lead the p...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.